Myriad Genetics, Inc. Forecast, price target & analysts
Myriad Genetics, Inc. Target price 2025 - Analyst rating & recommendation
Myriad Genetics, Inc. Classifications & Recommendation:
Myriad Genetics, Inc. Price Target
| Target Price | $14.84 |
| Price | $7.50 |
| Potential |
97.92%
register free of charge
|
| Number of Estimates | 16 |
|
16 Analysts have issued a price target Myriad Genetics, Inc. 2026 .
The average Myriad Genetics, Inc. target price is $14.84.
This is
97.92%
register free of charge
$29.00
286.67%
register free of charge
$8.00
6.67%
register free of charge
|
|
| A rating was issued by 17 analysts: 7 Analysts recommend Myriad Genetics, Inc. to buy, 6 to hold and 4 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Myriad Genetics, Inc. stock has an average upside potential 2026 of
97.92%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 837.60 | 844.85 |
| 11.21% | 0.87% | |
| EBITDA Margin | -3.10% | 3.40% |
| 67.25% | 209.53% | |
| Net Margin | -15.37% | -6.88% |
| 60.13% | 55.24% |
17 Analysts have issued a sales forecast Myriad Genetics, Inc. 2025 . The average Myriad Genetics, Inc. sales estimate is
This results in the following potential growth metrics:
14 Analysts have issued an Myriad Genetics, Inc. EBITDA forecast 2025. The average Myriad Genetics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
10 Myriad Genetics, Inc. Analysts have issued a net profit forecast 2025. The average Myriad Genetics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.41 | -0.64 |
| 55.66% | 54.61% | |
| P/E | negative | |
| EV/Sales | 0.85 |
10 Analysts have issued a Myriad Genetics, Inc. forecast for earnings per share. The average Myriad Genetics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Myriad Genetics, Inc....
Current Myriad Genetics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Apr 17 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Apr 09 2025 |
| Scotiabank |
Locked
➜
Locked
|
Locked | Apr 01 2025 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Mar 12 2025 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Mar 04 2025 |
| B of A Securities |
Locked
➜
Locked
|
Locked | Mar 03 2025 |
| Raymond James |
Locked
➜
Locked
|
Locked | Feb 25 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Apr 17 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Apr 09 2025 |
|
Locked
Scotiabank:
Locked
➜
Locked
|
Apr 01 2025 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Mar 12 2025 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Mar 04 2025 |
|
Locked
B of A Securities:
Locked
➜
Locked
|
Mar 03 2025 |
|
Locked
Raymond James:
Locked
➜
Locked
|
Feb 25 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
